Resultados da quimioembolização transarterial do carcinoma hepatocelular como terapia ponte para transplante de fígado

Radiol Bras. rb Radiologia Brasileira Radiol Bras 1678-7099 Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem Resumo Objetivo: Avaliar os resultados da necrose tumoral após quimioembolização transarterial (TACE) como terapia ponte e seu reflexo na sobrevida dos pacientes. Materiais e Métodos: Estudo de coorte retrospectivo, com 118 pacientes que realizaram TACE, em que foram avaliados o grau de necrose tumoral no explante e a sobrevida pós-transplante. Resultados: Necrose total do nódulo neoplásico no explante foi observada em 76 pacientes (64,4%). Observou-se que 77,8% dos pacientes com necrose total no explante hepático tinham apresentado resposta completa nos exames de imagem. A DEB-TACE, apesar de ter demonstrado menor taxa de intercorrências, proporcionou menor grau de necrose total em relação à TACE convencional, a despeito de não haver diferença estatística. Ao final do seguimento do estudo, o número de óbitos foi de 26. A sobrevida foi maior nos pacientes que tiveram necrose total quando comparada com grau de necrose parcial ou ausência de necrose [HR = 2,24 (IC 95%: 0,91-5,53); p = 0,078]. Conclusão: Necrose completa do tumor nos pacientes submetidos a TACE como terapia ponte parece estar associada com melhora da sobrevida. INTRODUCTION Hepatocellular carcinoma (HCC) accounts for approximately 75-85% of cases of primary liver neoplasms(1). Despite the various existing therapeutic proposals, liver transplantation is the ideal treatment because it removes the cancer and provides a cure for the underlying chronic liver disease. The significant limitation in its indication is the disproportionality between the number of donors and that of patients awaiting transplantation. Therefore, it should be indicated judiciously(2-4). Within the medical community, there is great concern regarding the possibility of patient dropout from transplant waiting lists. For patients on the waiting list for liver transplantation, failure to provide a bridging therapy has been shown to result in a dropout rate as high as 25% in six months and 38% in one year(5). When the time on the waiting list exceeds six months, locoregional therapy is recommended(5-7). The aim of such therapy is to control the tumor, improve transplant outcomes, and exclude HCCs that are biologically more aggressive(8). However, there is controversy regarding this practice(8-11). Locoregional therapies, such as transarterial embolization, transarterial chemoembolization (TACE), transarterial radioembolization, local ablation therapies, stereotactic body radiation, and combinations of those strategies, have been considered for use as bridging therapies. As a rule, those pre-transplant therapies do not provoke severe adverse events, although minor complications reportedly occur in 2.3-8.3% of cases(12,13). No superiority has been demonstrated among the proposed methods(5). However, among the procedures used as bridging therapies, we highlight TACE(14) because it is the most widely used. There are two types of TACE techniques-conventional TACE and drug-eluting bead TACE (DEB-TACE)-and the latter is theoretically associated with fewer toxic systemic effects(15). Most studies have shown no significant difference between the two techniques in terms of patient survival rates(15,16). The objective of the present study is to assess the degree of tumor necrosis after TACE, used as a bridging therapy, in patients on the waiting list for liver transplantation. A secondary objective was to evaluate the effect that the use of TACE has on post-transplant patient survival. MATERIALS AND METHODS This was a retrospective cohort study that included patients ≥ 18 years of age with a diagnosis of HCC who underwent TACE, as a bridging therapy to liver transplantation, between January 2013 and December 2021 at a public tertiary hospital in southern Brazil. The study was approved by the Research Ethics Committee of the Irmandade Santa Casa de Misericórdia de Porto Alegre, in the city of Porto Alegre, Brazil. The diagnosis of HCC was established by using triple-phase computed tomography or gadolinium contrast-enhanced magnetic resonance imaging as dynamic imaging techniques, in accordance with the guidelines established by the American Association for the Study of Liver Diseases(5). When necessary, a liver biopsy was performed. When the expected time on the waiting list was more than six months, TACE was recommended. In all cases, conventional TACE or DEB-TACE was carried out by an experienced interventional radiologist. Superselective catheterization was performed in most cases. The chemotherapy drug utilized was doxorubicin (1 mL diluted in 2-3 mL of lipiodol). Patients undergoing TACE as a definitive palliative therapy or for an indication other than the treatment of HCC were excluded, as were those for whom the data in the medical record were incomplete. Of 480 eligible patients, 136 met the inclusion criteria. The histology report was missing in 18 cases. Therefore, the final sample comprised 118 patients. The following patient characteristics were evaluated: age, gender, etiology of cirrhosis, and Child-Pugh score. Patients were classified, regarding whether or not liver transplantation was indicated, according to the Milan criteria(3). For HCCs, the variables studied were the number of nodules, the diameter of the largest nodule, the presence of portal vein thrombosis, and the alpha-fetoprotein (AFP) level at the time of diagnosis. An AFP cut-off of 100 ng/mL has previously been established(17). The arterial chemoembolization procedure was evaluated regarding the number of sessions, chemotherapeutic drugs used, complications after TACE, and response to TACE. The response to TACE was evaluated as described in the Modified Response Evaluation Criteria in Solid Tumor (mRECIST) guidelines(18) and was correlated with the degree of tumor necrosis of HCC in the liver explant. In the explanted liver, the degree of tumor differentiation (when total necrosis of the lesion was not achieved), the presence of satellite nodules, and microvascular invasion, as well as the degree of necrosis observed in the largest lesion, were evaluated by an experienced liver pathologist. In assessing the degree of tumor differentiation, we used the histological classification devised by the Liver Cancer Study Group of Japan(19). The number of deaths, in relation to the degree of necrosis of the liver explant, was recorded. The patients were followed until death or until the last outpatient visit in December 2021. Survival was calculated from the time of liver transplantation. Quantitative data are expressed as mean, standard deviation, and range. Categorical data are expressed as absolute values and percentages. Quantitative data were compared between groups by using analysis of variance or the Kruskal-Wallis test. For categorical data, we used Fisher’s exact test for comparisons. Poisson regression was used to compare event counts and to estimate incidence densities. Kaplan-Meier curves and a Cox regression model were used for the survival analysis. Values of p < 0.05 were deemed statistically significant. All analyses were conducted with the IBM SPSS Statistics software package, version 25.0 (IBM Corp., Armonk, NY, USA). RESULTS Initially, 136 patients were included in the study. The sociodemographic and clinical characteristics of the patients can be seen in Table 1. The degree of necrosis was evaluated by consulting the description of the explanted liver on the histopathology reports. Among the 118 patients selected for analysis, total necrosis in the explant was reported in 76 (64.4%). The degree of liver necrosis was not found to correlate with the etiology of liver disease (Table 2). Table 1 Sociodemographic and clinical characteristics of patients undergoing chemoembolization and liver transplantation. Characteristic (n = 136) Age (years), mean ± SD 61.5 ± 7.0 Gender, n (%) Male 103 (75.7) Female 33 (24.3) Cirrhosis etiology, n (%) Hepatitis C virus 77 (56.6) Hepatitis C virus+alcoholic liver disease 24 (17.6) Alcoholic liver disease 11 (8.1) Nonalcoholic steatohepatitis 10 (7.4) Hepatitis B virus 6 (4.4) Hepatitis C virus+hepatitis B virus 3 (2.2) Hepatitis B virus+alcoholic liver disease, hemochromatosis, or cryptogenesis 5 (3.7) Child-Pugh score, n (%)* A 104 (79.4) B+C 27 (20.6) * Data available for only 131 patients. SD, standard deviation. Table 2 Characteristics of patients, by the degree of necrosis observed in the histopathological examination of the liver explant (n = 118). Characteristic Degree of necrosis P None (n = 13) Partial (n = 29) Total (n = 76) Age (years), mean ± SD 59.5 ± 6.9 62.4 ± 6.9 62.0 ± 7.0 0.428* Male, n (%) 9 (69.2) 25 (86.2) 57 (75.0) 0.343† Cirrhosis etiology, n (%) 0.852† Hepatitis C virus 8 (61.5) 15 (51.7) 43 (56.6) Hepatitis C virus+alcoholic liver disease 2 (15.4) 6 (20.7) 14 (18.4) Alcoholic liver disease 1 (7.7) 4 (13.8) 5 (6.6) Nonalcoholic steatohepatitis 2 (15.4) 2 (6.9) 4 (5.3) Hepatitis B virus - - 5 (6.6) Hepatitis C virus+hepatitis B virus - - 2 (2.6) Hepatitis B virus+alcoholic liver disease, hemochromatosis, or cryptogenesis - 2 (6.9) 3 (3.9) Child-Pugh score A, n/total (%) 10/13 (76.9) 21/28 (75.0) 60/73 (82.2) 0.685† Milan criteria, n/total (%) 0.024† 1 nodule ≤ 5 cm 5/10 (50.0) 8/26 (30.8) 42/68 (61.8) 2-3 nodules ≤ 3 cm 5/10 (50.0) 18/26 (69.2) 26/68 (38.2) Number of nodules. mean ± SD 3.54 ± 3.18 2.69 ± 2.35 2.00 ± 1.56 0.002‡ Size of the largest nodule (cm), mean ± SD 2.73 ± 1.50 3.08 ± 0.95 2.96 ± 1.20 0.540§ AFP ≥ 100 ng/mL, n/total (%) 3/11 (27.3) 4/23 (17.4) 13/63 (20.6) 0.862† Portal thrombosis, n/total (%) 0/13 (0.0) 3/29 (10.3) 6/74 (8.1) 0.587† TACE number 1.1 1.3 1 < 0.001† Degree of tumor differentiation, n/total (%) > 0.99 1 1/10 (10.0) 4/27 (14.8) - 2 8/10 (80.0) 21/27 (77.8) - 3 1/10 (10.0) 2/27 (7.4) - Microvascular invasion, n/total (%) 2/13 (15.4) 8/29 (27.6) 4/75 (5.3) 0.004† Satellite nodules, n/total (%) 5/13 (38.5) 5/29 (17.2) 12/74 (16.2) 0.216† mRECIST response, n/total (%) < 0.001 Complete 2/12 (16.7) 12/26 (46.2) 56/72 (77.8) Partial 5/12 (41.7) 12/26 (46.2) 13/72 (18.1) Stable or progressive disease 5/12 (41.7) 2/26 (7.7) 3/72 (4.2) Death, n (%) 1 (7.7) 9 (31.0) 9 (11.8) 0.048† * Analysis of variance. † Fisher’s exact test. ‡ Poisson regression. § Kruskal-Wallis test. SD, standard deviation. Applying the Milan criteria, we identified a statistically significant difference, in terms of the degree of necrosis, between the patients with only one nodule ≤ 5 cm and those with two or three nodules ≤ 3 cm (p = 0.024); the proportion of patients with total necrosis in the explant after chemoembolization was greater among those with only one nodule ≤ 5 cm (61.8% vs. 38.2%). This was also confirmed in the analysis of the number of nodules in relation to the degree of necrosis after TACE, a lower number of nodules prior to chemoembolization having been found to be statistically significant for achieving total necrosis in the explant (p = 0.002). There was no statistically significant difference regarding the size of the nodule after chemoembolization. In the AFP analysis, when the cut-off of 100 ng/mL was used, there was no significant difference in the degree of necrosis. The mean number of chemoembolization procedures performed in patients with no, partial, and total necrosis was 1.1, 1.3, and 1, respectively. There was no statistical difference between the patients with no necrosis (n = 10) and those with partial necrosis (n = 27), in terms of the degree of tumor differentiation (p > 0.99). Most of the patients with total necrosis after undergoing the procedure had no microvascular invasion in the explant (p = 0.004). There was no correlation between total necrosis and a lower number of satellite nodules. When we looked for a correlation between the mRECIST response and total necrosis in the explant, we found that 77.8% of the patients with total necrosis in the explanted liver had presented a complete response by the mRECIST classification (p < 0.001). Computed tomography was the method utilized for analyses of the mRECIST response in most patients (in some cases magnetic resonance imaging was utilized), which was performed between one and two months after TACE. The time between imaging and liver transplantation was not more than five months. Figure 1 shows a complete response of the tumor after TACE. Figure 1 A: Computed tomography scan showing a LI-RADS category 5 lesion in the right lobe. B: Superselective angiography showing a hypervascular lesion. C: Follow-up angiography, performed at the end of the procedure, showing the devascularized lesion. D: Follow-up magnetic resonance imaging scan, acquired 60 days after the procedure, showing no gadolinium uptake by the tumor. The particles used in chemoembolization therapy were also analyzed and compared regarding their effectiveness in promoting necrosis in the tumor (Table 3). Polyvinyl alcohol, Embosphere, and Bead Block microspheres produced better results than did the HepaSphere microspheres (used in DEB-TACE). The HepaSphere particle provided total necrosis in 43.8% of the cases, compared with approximately 70% for the other particles, although there was no statistical difference. The rate of complications was lower for use of the HepaSphere particle, but, again, there was no statistical difference (p = 0.465). Table 3 Comparison of particles used in the chemoembolization procedure for HCCs. Variable HepaSphere* Embosphere Polyvinyl alcohol Bead Block P Degree of necrosis, n/total (%) 0.203 Total 14/32 (43.8) 27/39 (69.2) 19/25 (76.0) 13/17 (76.5) Partial 12/32 (37.5) 8/39 (20.5) 4/25 (16.0) 3/17 (17.6) None 6/32 (18.8) 4/39 (10.3) 2/25 (8.0) 1/17 (5.9) Complication(s), n/total (%) 3/39 (7.7) 4/45 (8.9) 3/26 (11.5) 4/19 (21.1) 0.465 Child-Pugh score, n/total (%) 0.432 A 29/38 (76.3) 35/43 (81.4) 21/26 (80.8) 12/17 (70.6) B 9/38 (23.7) 8/43 (18.6) 5/26 (19.2) 5/17 (29.4) Milan criteria, n/total (%) 0.762 1 nodule ≤ 5 cm 17/32 (53.1) 23/42 (54.8) 10/23 (43.5) 11/18 (61.1) 2-3 nodules ≤ 3 cm 15/32 (46.9) 19/42 (45.2) 13/23 (56.5) 7/18 (38.9) * DEB-TACE. Of the 136 patients evaluated, 16 (11.76%) had complications related to TACE: abdominal pain was the most common. Two of those patients had post-chemoembolization syndrome, but they recovery satisfactorily. When we analyzed the sample as a whole, using the Kaplan-Meier curve, we observed that the survival rate was 87.3% at one year, 82.1% at two years, 80.9% at three years, and 77.5% at five years. The median follow-up time was 43.7 months (Figure 2). Figure 2 Survival rate and follow-up time. By the end of the study follow-up period, 26 of the patients had died. The leading causes of death were postoperative complications of liver transplantation, in 12 (46.2%), causes unrelated to the tumor (infection), in 10 (38.5%), and progressive neoplastic disease, in 4 (15.4%). Because the number of deaths among the patients without necrosis was very small, they were grouped with those among the patients with partial necrosis, and there was a trend toward lower mortality among the patients with total necrosis than among those with partial/no necrosis. Of the 42 patients without total necrosis in the explant, 10 (23.8%) died, compared with only nine (11.8%) of the 76 with total necrosis. Therefore, as shown in Figure 3, the mortality rate in the group of patients with total necrosis (2.8 deaths/1,000 patient-months) was lower than was that in the group without (6.97 deaths/1,000 patient-months), with a hazard ratio of 2.24 (95% CI: 0.91-5.53), although the difference was less than significant (p = 0.078). Figure 3 Survival rate in relation to the degree of necrosis and follow-up time. DISCUSSION HCC is the sixth most common malignant neoplasm and the third leading cause of cancer-related death worldwide. It is a significant cause of morbidity and mortality in patients with cirrhosis(20). Liver transplantation is the ideal treatment for patients with HCC. However, the shortage of organs available for donation requires careful prioritization of patients on the transplant waiting list. Locoregional therapy has been offered to waitlisted patients to avoid dropout(5-7,13). Nevertheless, there is no consensus regarding this approach in the literature, mainly because of the difficulty of performing randomized, controlled prospective studies(5,12,21,22). In the present study, in which we analyzed a sample of more than 100 patients undergoing TACE as a bridging therapy, total tumor necrosis in the explant did not differ significantly from incomplete necrosis in terms of survival, despite the longer survival of the patients with total necrosis. As in other studies in the Western literature, the average age of the patients was approximately 60 years, most of the patients were male, and the most common etiology of cirrhosis was infection with hepatitis C virus. The most representative Child-Pugh score was A, and most patients also met the Milan criteria(23-25). In our study sample, total necrosis was observed mainly in the patients with a solitary nodule. In the patients with multiple nodules, achieving total necrosis was related to a lower number of nodules. Other authors have also reported that the achievement of total necrosis is more common among patients with a solitary nodule(26). In the present study, there was no difference in the degree of necrosis in relation to the size of the largest nodule, the degree of tumor differentiation (although this was evaluated only in the patients without total necrosis), or the AFP level. Some authors consider a low AFP level to be an independent predictor of total necrosis(26,27). Of the patients with total necrosis in our sample, most had no microvascular invasion in the explant, suggesting that the risk of vascular invasion was lower in that group of patients. The mean number of procedures performed in our sample was lower than the 2.5 ± 1.5 reported in the literature(28). The reported level of interobserver agreement between radiologists for the presence or absence of a Liver Imaging Reporting and Data System (LI-RADS) category 5 lesion was excellent when mRECIST criteria were utilized(29). In the evaluation of the tumor response after TACE, according to the mRECIST classification, a correlation has been observed between the mRECIST response and total necrosis in the liver explant, nearly 80% of patients with total necrosis in the explant having been found to show a complete response according to the mRECIST classification(19). In the present study, survival was greater among the patients with total necrosis, although the difference in comparison with the other patients did not reach statistical significance, which is probably due to the relatively small sample size. The mortality rate was lower among the patients with total necrosis than among those without. Similar findings were reported by Allard et al.(26), although their study demonstrated a lower incidence of tumor recurrence in patients with total necrosis. A multicenter study analyzing a large patient sample showed that when total necrosis was achieved, survival was longer and the tumor recurrence rate was lower(8). However, when the sample as a whole was evaluated, no difference in the outcomes was observed between the patients who underwent bridging therapy and those who did not, regardless of the degree of necrosis achieved. Similar results regarding total necrosis were obtained in another large multicenter study(28). It should be borne in mind that those studies also evaluated other modalities of locoregional therapy and not only TACE. Systematic reviews focusing on bridging therapy are generally of poor quality, showing either improved survival when bridging therapy is used(22) or demonstrating its ineffectiveness(23). Recently, Butcher et al.(30) showed that individuals treated with TACE, despite having worse prognostic characteristics (in terms of tumor diameter and longer time on the waiting list), had survival and postoperative outcomes similar to those of patients who did not undergo bridging therapy. However, their analysis included patients with tumors that had been downstaged. The most recent systematic review and meta-analysis on the topic in question(12), using the concept of intention-to-treat in an original way, concluded that patients undergoing bridging therapy before liver transplantation, despite being on the waiting list for longer than those who did not undergo the procedure, had better post-transplant survival. Nevertheless, when the intention-to-treat analysis was performed, there was no difference between those two groups in terms of the one-, three-, or five-year survival rate. As limitations in the present study, we call attention mainly to its retrospective nature, the fact that we did not evaluate the incidence of tumor recurrence, and the relatively small number of patients evaluated. If we had analyzed a larger cohort, the better survival of patients with total necrosis in the explant might have reached statistical significance. CONCLUSION This real-life study revealed that, in patients undergoing TACE as a bridging therapy, total tumor necrosis appears to be associated with improved patient survival. However, prospective controlled studies are needed in order to obtain a more definitive answer regarding the best practice in patients on the waiting list for liver transplantation. REFERENCES 1 1 Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. Balogh J Victor D 3rd Asham EH Hepatocellular carcinoma: a review J Hepatocell Carcinoma 2016 3 41 53 2 2 Clavien PA, Lesurtel M, Bossuyt PMM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-22. Clavien PA Lesurtel M Bossuyt PMM Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 2012 13 e11 22 3 3 Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9. Mazzaferro V Regalia E Doci R Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 1996 334 693 699 4 4 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38. Llovet JM Brú C Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 1999 19 329 338 5 5 Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-80. Heimbach JK Kulik LM Finn RS AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 2018 67 358 380 6 6 European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 2018 69 182 236 7 7 Chagas AL, Mattos AA, Carrilho FJ, et al. Brazilian Society of Hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2020;57(suppl 1):1-20. Chagas AL Mattos AA Carrilho FJ Brazilian Society of Hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma Arq Gastroenterol 2020 57 suppl 1 1 20 8 8 Agopian VG, Harlander-Locke MP, Ruiz RM, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium. Ann Surg. 2017;266:525-35. Agopian VG Harlander-Locke MP Ruiz RM Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium Ann Surg 2017 266 525 535 9 9 Kim JM, Kwon CHD, Joh JW, et al. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria. Transplant Proc. 2012;44:403-8. Kim JM Kwon CHD Joh JW Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria Transplant Proc 2012 44 403 408 10 10 Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2005;11:767-75. Decaens T Roudot-Thoraval F Bresson-Hadni S Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma Liver Transpl 2005 11 767 775 11 11 Lee S, Kim KW, Song GW, et al. The real impact of bridging or downstaging on survival outcomes after liver transplantation for hepatocellular carcinoma. Liver Cancer. 2020;9:721-33. Lee S Kim KW Song GW The real impact of bridging or downstaging on survival outcomes after liver transplantation for hepatocellular carcinoma Liver Cancer 2020 9 721 733 12 12 Di Martino M, Ferraro D, Pisaniello D, et al. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes. J Hepatobiliary Pancreat Sci. 2023;30:429-38. Di Martino M Ferraro D Pisaniello D Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes J Hepatobiliary Pancreat Sci 2023 30 429 438 13 13 Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92-9. Sapisochin G Barry A Doherty M Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis J Hepatol 2017 67 92 99 14 14 Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-57. Mazzaferro V Bhoori S Sposito C Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience Liver Transpl 2011 17 Suppl 2 S44 57 15 15 Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. Lammer J Malagari K Vogl T Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 2010 33 41 52 16 16 Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-64. Golfieri R Giampalma E Renzulli M Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma Br J Cancer 2014 111 255 264 17 17 Lionço LC, Mattos AA, Horbe AF, et al. Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. Eur J Gastroenterol Hepatol. 2017;29:225-30. Lionço LC Mattos AA Horbe AF Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil Eur J Gastroenterol Hepatol 2017 29 225 230 18 18 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60. Lencioni R Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 2010 30 52 60 19 19 No authors listed. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 1989;19:98-129. No authors listed The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan Jpn J Surg 1989 19 98 129 20 20 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49. Sung H Ferlay J Siegel RL Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 249 21 21 Morris PD, Laurence JM, Yeo D, et al. Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review. Liver Transpl. 2017;23:375-85. Morris PD Laurence JM Yeo D Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review Liver Transpl 2017 23 375 385 22 22 Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381-400. Kulik L Heimbach JK Zaiem F Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis Hepatology 2018 67 381 400 23 23 Appel-da-Silva MC, Miozzo SAS, Dossin IA, et al. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: a 10-year retrospective cohort study. World J Gastroenterol. 2016; 22:10219-25. Appel-da-Silva MC Miozzo SAS Dossin IA Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: a 10-year retrospective cohort study World J Gastroenterol 2016 22 10219 25 24 24 Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-93. Reig M Forner A Rimola J BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update J Hepatol 2022 76 681 693 25 25 Carrilho FJ, Kikuchi L, Branco F, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (São Paulo). 2010;65:1285-90. Carrilho FJ Kikuchi L Branco F Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil Clinics (São Paulo) 2010 65 1285 1290 26 26 Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol. 2015;63:83-92. Allard MA Sebagh M Ruiz A Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol 2015 63 83 92 27 27 DiNorcia J, Florman SS, Haydel B, et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271:616-24. DiNorcia J Florman SS Haydel B Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium Ann Surg 2020 271 616 624 28 28 Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. Marelli L Stigliano R Triantos C Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 2007 30 6 25 29 29 Pereira RCR, Heming CAM, Tejo TR, et al. Use of the LIRADS classification in patients with cirrhosis due to infection with hepatitis B, C, or D, or infected with hepatitis B and D. Radiol Bras. 2020;53:14-20. Pereira RCR Heming CAM Tejo TR Use of the LIRADS classification in patients with cirrhosis due to infection with hepatitis B, C, or D, or infected with hepatitis B and D Radiol Bras 2020 53 14 20 30 30 Butcher DA, Brandis KJ, Wang H, et al. Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48:621-31. Butcher DA Brandis KJ Wang H Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: a systematic review and meta-analysis Eur J Surg Oncol 2022 48 621 631